The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis

BMC Cancer

Yoshiki Murakami³  Akihiro Tamori³  Saori Itami³  Toshihito Tanahashi⁷  Hidenori Toyoda²  Masami Tanaka¹  Weihong Wu⁵  Nariso Brojigin⁵  Yuji Kaneoka⁴  Atsuyuki Maeda⁴  Takashi Kumada²  Norifumi Kawada³  Shoji Kubo⁶  Masahiko Kuroda⁵ 

[1] Present address: Laboratory of Genome Technology, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, 108-8679, Japan

[2] Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, 503-8502, Japan

[3] Department of Hepatology, Graduate School of Medicine Osaka City University, Osaka, 545-8585, Japan

[4] Department of Surgery, Ogaki Municipal Hospital, Ogaki, 503-8502, Japan

[5] Department of Molecular Pathology, Tokyo Medical University, Tokyo, 160-8402, Japan

[6] Department of Hepato-Biliary-Pancreatic Surgery, Graduate School of Medicine, Osaka City University, Osaka, 545-8585, Japan

[7] Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan

关键词: TNRC6B;    Biomarker;    miRNA;    Histological differentiation;    Hepatocellular carcinoma;   

Others  :  1079891
DOI  :  10.1186/1471-2407-13-99

 received in 2012-11-12, accepted in 2013-02-27,  发布年份 2013

【 摘 要 】

Background

Many studies support the hypothesis that specific microRNA (miRNA) expression in various human cancers including hepatocarcinogenesis is closely associated with diagnosis and prognosis. In hepatocellular carcinoma (HCC), malignancy level is related to the degree of histological differentiation.

Methods

In order to establish a novel biomarker that can determine the degree of malignancy and forecast patient prognosis, we performed a microarray analysis to investigate the miRNA expression profiles in 110 HCC which were comprised of 60 moderately, 30 poorly, and 20 well differentiated HCC.

Results

We found that the expression of 12 miRNAs varied significantly according to the degree of histological differentiation. Particularly, miR-18b expression in poorly differentiated HCC was significantly higher than in well differentiated HCC. Based on miRanda and Targetscan target search algorithms and Argonaute 2 immunoprecipitation study, we noted that miR-18b can control the expression of trinucleotide repeat containing 6B (TNRC6B) as a target gene. Additionally, in two hepatoma cell lines, we found that over-expression of miR-18b or down-regulation of TNRC6B accelerated cell proliferation and loss of cell adhesion ability. Finally, we observed that after surgical resection, HCC patients with high miR-18b expression had a significantly shorter relapse-free period than those with low expression.

Conclusions

miR-18b expression is an important marker of cell proliferation and cell adhesion, and is predictive of clinical outcome. From a clinical point of view, our study emphasizes miR-18b as a diagnostic and prognostic marker for HCC progression.

【 授权许可】

   
2013 Murakami et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. Cancer J Clin 2002, 55(2):74-108.
• [2]Brechot C, Gozuacik D, Murakami Y, Paterlini-Brechot P: Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000, 10(3):211-231.
• [3]Thorgeirsson SS, Lee JS, Grisham JW: Functional genomics of hepatocellular carcinoma. Hepatology 2006, 43(2 Suppl 1):S145-S150.
• [4]Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007, 27(1):55-76.
• [5]Pierce GB, Speers WC: Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 1988, 48(8):1996-2004.
• [6]Sakamoto M, Hirohashi S, Shimosato Y: Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991, 22(2):172-178.
• [7]Kubo S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Ikebe T, Yamamoto T, Wakasa K, Nishiguchi S, Kuroki T: Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. World J Surg 2000, 24(12):1559-1565.
• [8]Ambros V: The functions of animal microRNAs. Nature 2004, 431(7006):350-355.
• [9]Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K: Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006, 25(17):2537-2545.
• [10]Braconi C, Patel T: MicroRNA expression profiling: a molecular tool for defining the phenotype of hepatocellular tumors. Hepatology 2008, 47(6):1807-1809.
• [11]Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM: MicroRNA expression, survival, and response to interferon in liver cancer. New Eng J Med 2009, 361(15):1437-1447.
• [12]Murakami Y, Tanaka M, Toyoda H, Hayashi K, Kuroda M, Tajima A, Shimotohno K: Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Med Genomics 2010, 3:48. BioMed Central Full Text
• [13]Murakami Y, Toyoda H, Tanaka M, Kuroda M, Harada Y, Matsuda F, Tajima A, Kosaka N, Ochiya T, Shimotohno K: The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One 2011, 6(1):e16081.
• [14]Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, Yu L, Bai S, La Perle K, Chivukula RR: Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012, 122(8):2871-2883.
• [15]Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF: MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012, 122(8):2884-2897.
• [16]Bjork JK, Sandqvist A, Elsing AN, Kotaja N, Sistonen L: miR-18, a member of Oncomir-1, targets heat shock transcription factor 2 in spermatogenesis. Development 2010, 137(19):3177-3184.
• [17]Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY: MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011, 140(5):1618-1628.
• [18]Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H, Verma A: Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uerine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003, 162(6):1789-1806.
• [19]Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K: Toward the blood-borne miRNome of human diseases. Nat Methods 2011, 8(10):841-843.
• [20]Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A: miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 2010, 107(1):264-269.
• [21]Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, Chen DS, Chen PJ: MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 2009, 136(2):683-693.
• [22]Fu X, Wang Q, Chen J, Huang X, Chen X, Cao L, Tan H, Li W, Zhang L, Bi J: Clinical significance of miR-221 and its inverse correlation with p27Kip(1) in hepatocellular carcinoma. Mol Biol Rep 2011, 38(5):3029-3035.
• [23]Zhang J, Yang Y, Yang T, Liu Y, Li A, Fu S, Wu M, Pan Z, Zhou W: microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer 2010, 103(8):1215-1220.
• [24]Kahlert C, Klupp F, Brand K, Lasitschka F, Diederichs S, Kirchberg J, Rahbari N, Dutta S, Bork U, Fritzmann J: Invasion front-specific expression and prognostic significance of microRNA in colorectal liver metastases. Cancer Sci 2011, 102(10):1799-1807.
• [25]Meister G, Landthaler M, Peters L, Chen PY, Urlaub H, Luhrmann R, Tuschl T: Identification of novel argonaute-associated proteins. Curr Biol 2005, 15(23):2149-2155.
• [26]Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J: Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008, 40(3):316-321.
• [27]Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Eeles RA, Easton DF, Foulkes WD, Simard J: A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 2005, 77(2):219-229.